Is Integrative Medicine the Future? Relman-Weil debate focuses on scientific evidence issues

Edited by: Steve Bunk Arnold S. RelmanAndrew Weil Integrative medicine, the combining of alternative and conventional medical methods, was the subject of a debate held recently at the University of Arizona (UA) College of Medicine. The opponents were Arnold S. Relman, editor-in-chief emeritus of the New England Journal of Medicine and professor emeritus of medicine and social medicine at Harvard Medical School, and Andrew Weil, director of the UA program in integrative medicine and best-selli

Written bySteve Bunk
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Edited by: Steve Bunk

Arnold S. Relman
Andrew Weil
Integrative medicine, the combining of alternative and conventional medical methods, was the subject of a debate held recently at the University of Arizona (UA) College of Medicine. The opponents were Arnold S. Relman, editor-in-chief emeritus of the New England Journal of Medicine and professor emeritus of medicine and social medicine at Harvard Medical School, and Andrew Weil, director of the UA program in integrative medicine and best-selling author of eight books that have made the Harvard-educated physician a leading advocate of integrative medicine. Last December, an article by Relman appeared in The New Republic that sharply attacked Weil's writings.1 Their subsequent debate consisted of opening remarks, rebuttals, questions, and closing remarks that have been edited in the following text. Sentences and paragraphs have been deleted or transposed where appropriate.

Relman: Integrating alternative medicine with mainstream medicine, as things stand now, would not ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies